Oppenheimer Issues Pessimistic Forecast for Chemomab Therapeutics (NASDAQ:CMMB) Stock Price

Chemomab Therapeutics (NASDAQ:CMMB) had its target price lowered by equities researchers at Oppenheimer from $11.00 to $10.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock.

Separately, Maxim Group increased their price target on Chemomab Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a report on Thursday, February 20th.

Chemomab Therapeutics Price Performance

NASDAQ CMMB opened at $1.37 on Friday. The company has a market cap of $19.67 million, a PE ratio of -1.37 and a beta of 0.55. The stock’s 50 day simple moving average is $1.21 and its 200-day simple moving average is $1.59. Chemomab Therapeutics has a 1-year low of $0.78 and a 1-year high of $2.55.

Chemomab Therapeutics (NASDAQ:CMMB) last released its earnings results on Thursday, May 15th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.06. On average, equities research analysts anticipate that Chemomab Therapeutics will post -1 EPS for the current fiscal year.

Institutional Investors Weigh In On Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. Virtu Financial LLC purchased a new stake in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 14,445 shares of the company’s stock, valued at approximately $26,000. Virtu Financial LLC owned about 0.10% of Chemomab Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 46.05% of the company’s stock.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).